New technologies for vaccine development

Drug Development Research

Volumn 62, Issue 4, 2004, Pages 383-392

  Srinivasan, Kellathur N ^a   Brusic, Vladimir ^b,c   August, Thomas J ^a,d  

^a Johns Hopkins Singapore   (Singapore)

^b INSTITUTE FOR INFOCOMM RESEARCH   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bioinformatics; Hot spots; T cell epitopes; Vaccines

Indexed keywords

CD45 ANTIGEN; CD8 ANTIGEN; DNA VACCINE; EPITOPE; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MEMBRANE PROTEIN; VACCINE;

ARTICLE; B LYMPHOCYTE; COMPUTER MODEL; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; HLA SYSTEM; HOST; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNIZATION; INNATE IMMUNITY; LYSOSOME; NONHUMAN; PATHOGENESIS; T LYMPHOCYTE; TECHNOLOGY; VACCINATION;

EID: 11344290828     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10393     Document Type: Article

References (118)

1. Abele R, Tampe R. 1999. Function of the transport complex TAP in cellular immune recognition. Biochim Biophys Acta 1461:405-419.
2. Ada G. 2003. Progress towards achieving new vaccines and vaccination goals. Int Med J 33:297-304.
3. Alam R. 1998. A brief review of the immune system. Prim Care 25:727-738.
4. Al Jabri AA. 2002. HLA and in vitro susceptibility to HIV infection. Mol Immunol 38:959-967.
5. Antoniou AN, Powis SJ, Elliott T. 2003. Assembly and export of MHC class I peptide ligands. Curr Opin Immunol 15:75-81.
6. Arif S, Tree TI, Astill TP, Tremble JM, Bishop AJ, Dayan CM, Roep BO, Peakman M. 2004. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J Clin Invest 113:451-463.
7. Arnon R, Ben-Yedidia T. 2003. Old and new vaccine approaches. Int Immunopharmacol 3:1195-1204.
8. Azzazy HM, Highsmith WE Jr. 2002. Phage display technology: clinical applications and recent innovations. Clin Biochem 35:425-145.
9. Bishop GA, Haxhinasto SA, Stunz LL, Hostager BS. 2003. Antigen-specific B-lymphocyte activation. Crit Rev Immunol 23:149-197.
10. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. 1987. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 329:506-512.
11. Britschgi M, von Greyerz S, Burkhart C, Pichler WJ. 2003. Molecular aspects of drug recognition by specific T cells. Curr Drug Targets 4:1-11.
12. Brown JH, Jardetzky TS, Gorga JC, Stern LJ, Urban RG, Strominger JL, Wiley DC. 1993. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 364:33-39.
13. Brusic V, Flower DR. 2004. Bioinformatics tools for identifying T-cell epitopes. Drug Discov Today Biosilico 1:18-23.
14. Brusic V, Rudy G, Harrison LC. 1998. MHCPEP, a database of MHC-binding peptides: update 1997. Nucleic Acids Res 26:368-371.
15. Brusic V, van Endert P, Zeleznikow J, Daniel S, Hammer J, Petrovsky N. 1999. A neural network model approach to the study of human TAP transporter. In Silico Biol 1:109-121.
16. Brusic V, Bucci K, Schonbach C, Petrovsky N, Zeleznikow J, Kazura JW. 2001. Efficient discovery of immune response targets by cyclical refinement of QSAR models of peptide binding. J Mol Graph Model 19:405-411.
17. Brusic V, Petrovsky N, Zhang G, Bajic VB. 2002. Prediction of promiscuous peptides that bind HLA class I molecules. Immunol Cell Biol 80:280-285.
18. Bryant PA, Venter D, Robins-Browne R, Curtis N. 2004. Chips with everything: DNA microarrays in infectious diseases. Lancet Infect Dis 4:100-111.
19. Busch R, Doebele RC, Patil NS, Pashine A, Mellins ED. 2000. Accessory molecules for MHC class II peptide loading. Curr Opin Immunol 12:99-106.
20. Capecchi B, Sernito D, Adu-Bobie J, Rappuoli R, Pizza M. 2004. The genome revolution in vaccine research. Curr Issues Mol Biol 6:17-27.
21. Carbone FR, Heath WR. 2003. The role of dendritic cell subsets in immunity to viruses. Curr Opin Immunol 15:416-420.
22. Chen JW, Murphy TL, Willingham MC, Pastan I, August JT 1985. Identification of two lysosomal membrane glycoproteins. J Cell Biol 101:85-95.
23. Chen JW, Chen GL, D'Souza MP, Murphy TL, August JT 1986. Lysosomal membrane glycoproteins: properties of LAMP-1 and LAMP-2. Biochem Soc Symp 51:97-112.
24. Cheng PC, Steele CR, Gu L, Song W, Pierce SK. 1999. MHC class II antigen processing in B cells: accelerated intracellular targeting of antigens. J Immunol 62:7171-7180.
25. Cohen ML. 2000. Changing patterns of infectious disease. Nature 406:762-767.
26. Collins KL, Baltimore D. 1999. HIVs evasion of the cellular immune response. Immunol Rev 168:65-74.
27. Cunha-Neto E. 1999. MHC-restricted antigen presentation and recognition: constraints on gene, recombinant and peptide vaccines in humans. Braz J Med Biol Res 32:199-205.
28. Daniel S, Brusic V, Caillat-Zucman S, Petrovsky N, Harrison L, Riganelli D, Sinigaglia F, Gallazzi F, Hammer J, van Endert PM. 1998. Relationship between peptide selectivities of human transporters associated with antigen processing and HLA class I molecules. J Immunol 161:617-624.
29. Davis HL, McCluskie MJ. 1999. DNA vaccines for viral diseases. Microbes Infect 1:7-21.
30. De Groot AS, Bosma A, Chinai N, Frost J, Jesdale BM, Gonzalez MA, Martin W, Saint-Aubin C. 2001. From genome to vaccine: in silico predictions, ex vivo verification. Vaccine 19:4385-4395.
31. de Arruda LB, Chikhlikar PR, August JT, Marques ET. 2004. DNA vaccine encoding human immunodeficiency virus-1 Gag, targeted to the major histocompatibility complex II compartment by lysosomal-associated membrane protein, elicits enhanced long-term memory response. Immunology 112:126-133.
32. De Lalla C, Sturniolo T, Abbruzzese L, Hammer J, Sidoli A, Sinigaglia F, Panina-Bordignon P. 1999. Cutting edge: identification of novel T cell epitopes in Lol p5a by computational prediction. J Immunol 163:1725-1729.
33. Del Guercio MF, Sidney J, Hermanson G, Ferez C, Grey HM, Kubo RT, Sette A. 1995. Binding of a peptide antigen to multiple HLA alleles allows definition of an A2-like supertype. J Immunol 154:685-693.
34. Dempsey PW, Vaidya SA, Cheng G. 2003. The art of war: innate and adaptive immune responses. Cell Mol Life Sci 60:2604-2621.
35. Dertzbaugh MT 1998. Genetically engineered vaccines: an overview. Plasmid 39:100-113.
36. Dietrich G. 2003. DNA microarrays in vaccine research. Curr Opin Mol Ther 5:575-583.
37. Donnelly JJ, Friedman A, Martinez D, Montgomery DL, Shiver JW, Motzel SL, Ulmer JB, Liu MA. 1995. Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nat Med 1:583-587.
38. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA. 1997. DNA vaccines. Annu Rev Immunol 15:617-648.
39. Donnelly JJ, Liu MA, Ulmer JB. 2000. Antigen presentation and DNA vaccines. Am J Respir Crit Care Med 162:8190-5193.
40. Doytchinova IA, Guan P, Flower DR. 2004. Identifying human MHC supertypes using bioinformatic methods. J Immunol 172:4314-4323.
41. Fabbri M, Smart C, Pardi R. 2003. T lymphocytes. Int J Biochem Cell Biol 35:1004-1008.
42. Feldtkeller E, Khan MA, van der Heijde D, van der Linden S, Braun J. 2003. Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int 23:61-66.
43. Flower DR. 2003. Towards in silico prediction of immunogenic epitopes. Trends Immunol 24:667-674.
44. Folch E, Hernandez I, Barragan M, Franco-Paredes C. 2003. Infectious diseases, non-zero-sum thinking, and the developing world. Am J Med Sci 326:66-72.
45. Furuta K, Ikeda M, Nakayama Y, Nakamura K, Tanaka M, Hamasaki N, Himeno M, Hamilton SR, August JT 2001. Expression of lysosome-associated membrane proteins in human colorectal neoplasms and inflammatory diseases. Am J Pathol 159:449-455.
46. Garmory HS, Brown KA, Titball RW. 2003. DNA vaccines: improving expression of antigens. Genet Vaccines Ther 1:2-6.
47. Grandi G. 2003. Rational antibacterial vaccine design through genomic technologies. Int J Parasitol 33:615-620.
48. Guan P, Doytchinova IA, Zygouri C, Flower DR. 2003. MHCPred: a server for quantitative prediction of peptide-MHC binding. Nucleic Acids Res 31:3621-3624.
49. Hattotuwagama CK, Guan P, Doytchinova IA, Zygouri C, Flower DR. 2004. Quantitative online prediction of peptide binding to the major histocompatibility complex. J Mol Graph Model 22:195-207.
50. Hendel H, Caillat-Zucman S, Lebuanec H, Carrington M, O'Brien S, Andrieu JM, Schachter F, Zagury D, Rappaport J, Winkler C, Nelson GW, Zagury JF. 1999. New class I and II HLA alleles strongly associated with opposite patterns of progression to AIDS. J Immunol 162:6942-6946.
51. Honeyman MC, Brusic V, Stone NL, Harrison LC. 1998. Neural network-based prediction of candidate T-cell epitopes. Nat Biotechnol 16:966-969.
52. Hung CF, Wu TC. 2003. Improving DNA vaccine potency via modification of professional antigen presenting cells. Curr Opin Mol Ther 5:20-24.
53. Huston DP. 1999. The biology of the immune system. JAMA 278:1804-1814.
54. Ishioka GY, Fikes J, Hermanson G, Livingston B, Crimi C, Qin M, del Guercio MF, Oseroff C, Dahlberg C, Alexander J, Chesnut RW, Sette A. 1999. Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes. J Immunol 162:3915-3925.
55. Kenney RT, Edelman R. 2003. Survey of human-use adjuvants. Expert Rev Vaccines 2:167-88.
56. Kipps TJ. 1997. The human B cell biology. Int Rev Immunol 15:243-264.
57. Kirkley JE, Goldstein AL, Naylor PH. 2001. Effect of peptide-carrier coupling on peptide-specific immune responses. Immunobiology 203:601-615.
58. Kobayashi H, Lu J, Celis E. 2001. Identification of helper T-cell epitopes that encompass or lie proximal to cytotoxic T-cell epitopes in the gp100 melanoma tumor antigen. Cancer Res 61:7577-7584.
59. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM, Wu TC. 1996. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56:21-26.
60. Liu R, Enstrom AM, Lam KS. 2003. Combinatorial peptide library methods for immunobiology research. Exp Hematol 31:11-30.
61. Liu YJ. 2001. Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell 106:259-262.
62. Lu Y, Raviprakash K, Leao IC, Chikhlikar PR, Ewing D, Anwar A, Chougnet C, Murphy G, Hayes CG, August TJ, Marques ET Jr. 2003. Dengue 2 PreM-E/LAMP chimera targeted to the MHC class II compartment elicits long-lasting neutralizing antibodies. Vaccine 21:2178-2189.
63. Lund O, Nielsen M, Kesmir C, Petersen AG, Lundegaard C, Worning P, Sylvester-Hvid C, Lamberth K, Roder G, Justesen S, Buus S, Brunak S. 2004. Definition of supertypes for HLA molecules using clustering of specificity matrices. Immunogenetics 55:797-810.
64. MacGregor RR, Ginsberg R, Ugen KE, Baine Y, Kang CU, Tu XM, Higgins T, Weiner DB, Boyer JD. 2002. T-cell responses induced in normal volunteers immunized with a DNA-based vaccine containing HIV-1 env and rev. AIDS. 16:2137-2143.
65. Mamitsuka H. 1998. Predicting peptides that bind to MHC molecules using supervised learning of hidden Markov models. Proteins 33:460-474.
66. Marques ET Jr, Chikhlikar P, de Arruda LB, Leao IC, Lu Y, Wong J, Chen JS, Byrne B, August JT 2003. HIV-1 p55Gag encoded in the lysosome-associated membrane protein-1 as a DNA plasmid vaccine chimera is highly expressed, traffics to the major histocompatibility class II compartment, and elicits enhanced immune responses. J Biol Chem 278:37926-37936.
67. McDonnell WM, Askari FK. 2000. DNA vaccines. N Engl J Med 334:42-45.
68. Moron G, Dadaglio G, Lelerc C. 2004. New tools for antigen delivery to MHC class I pathway. Trends Immunol 25:92-97.
69. Munn DH, Mellor AL. 2003. Macrophages and the regulation of self-reactive T cells. Curr Pharm Des 9:257-264.
70. Myers CD. 1991. Role of B cell antigen processing and presentation in the humoral immune response. FASEB J 5:2547-2553.
71. Nair SK, Boczkowski D, Morse M, Cumming RI, Lyerly HK, Gilboa E. 1998. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat Biotechnol 16:364-369.
72. Neefjes J. 1999. CIIV, MIIC and other compartments for MHC class II loading. Eur J Immunol 29:1421-1425.
73. Nordeng TW, Gorvel JP, Bakke O. 1998. Intracellular transport of molecules engaged in the presentation of exogenous antigens. Curr Top Microbiol Immunol 232:179-215.
74. Nossal GJ. 2003. The double helix and immunology. Nature 421:440-444.
75. Pamer E, Cresswell P. 1998. Mechanisms of MHC class I-restricted antigen processing. Annu Rev Immunol 16:323-358.
76. Panigada M, Sturniolo T, Besozzi G, Boccieri MG, Sinigaglia F, Grassi GG, Grassi F. 2002. Identification of a promiscuous T-cell epitope in Mycobacteriurn tuberculosis Mce proteins. Infect Immun 70:79-85.
77. Parker KC, Bednarek MA, Coligan JE. 1994. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 152:163-175.
78. Petrovsky N, Schonbach C, Brusic V. 2003. Bioinformatic strategies for better understanding of immune function. In Silico Biol 3:411-416.
79. Rammensee HG. 1995. Chemistry of peptides associated with MHC class I and II molecules. Curr Opin Immunol 7:85-96.
80. Rammensee HG. 1996. Antigen presentation - recent developments. Int Arch Allergy Immunol 110:299-307.
81. Raviprakash K, Marques E, Ewing D, Lu Y, Phillips I, Porter KR, Kochel TJ, August TJ, Hayes CG, Murphy GS. 2001. Synergistic neutralizing antibody response to a dengue virus type 2 DNA vaccine by incorporation of lysosome-associated membrane protein sequences and use of plasmid expressing GM-CSF. Virology 290:74-82.
82. Rock KL. 1996. A new foreign policy: MHC class I molecules monitor the outside world. Immunol Today 17:131-137.
83. Rock KL, Goldberg AL. 1999. Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu Rev Immunol 17:739-779.
84. Rodriguez F, An LL, Harkins S, Zhang J, Yokoyama M, Widera G, Fuller JT, Kincaid C, Campbell IL, Whirton JL. 1998. DNA immunization with minigenes: low frequency of memory cytotoxic T lymphocytes and inefficient antiviral protection are rectified by ubiquitination. J Virol 72:5174-5181.
85. Ruff AL, Guarnieri FG, Staveley-O'Carroll K, Siliciano RF, August JT. 1997. The enhanced immune response to the HIV gp160/LAMP chinieric gene product targeted to the lysosome membrane protein trafficking pathway. J Biol Chem 272:8671-8678.
86. Sarikaya M, Tamerler C, Jen AK, Schulten K, Baneyx F. 2003. Molecular biomimetics: nanotechnology through biology. Nat Mater 2:577-585.
87. Savoie CJ, Kamikawaji N, Sasazuki T, Kuhara S. 1999. Use of BONSAI decision trees for the identification of potential MHC class I peptide epitope motifs. Pac Symp Biocomput 182-189.
88. Saxova P, Buus S, Brunak S, Kesmir C. 2003. Predicting proteasomal cleavage sites: a comparison of available methods. Int Immunol 15:781-787.
89. Schirle M, Weinschenk T, Stevanovic S. 2001. Combining computer algorithms with experimental approaches permits the rapid and accurate identification of T cell epitopes from defined antigens. J Immunol Methods 257:1-16.
90. Schweiger B, Zadow I, Heckler R. 2002. Antigenic drift and variability of influenza viruses. Med Microbiol Immunol 191:133-138.
91. Sette A, Sidney J. 1998. HLA supertypes and supermotifs: a functional perspective on HLA polymorphism. Curr Opin Immunol 10:478-482.
92. Sette A, Sidney J. 1999. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 50:201-212.
93. Sidney J, Grey HM, Kubo RT, Sette A. 1996. Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs. Immunol Today 17:261-266.
94. Sospedra M, Pinilla C, Martin R. 2003. Use of combinatorial peptide libraries for T-cell epitope mapping. Methods 29:236-247.
95. Spiliotis ET, Manley H, Osorio M, Zuniga MC, Edidin M. 2000. Selective export of MHC class I molecules from the ER after their dissociation from TAP. Immunity 13:841-851.
96. Sproul TW, Cheng PC, Dykstra ML, Pierce SK. 2000. A role for MHC class II antigen processing in B cell development. Int Rev Immunol 19:139-155.
97. Srinivasan KN, Zhang GL, Khan AM, August JT, Brusic V. 2004. Prediction of class I T-cell epitopes: Evidence of presence of immunological hot spots inside antigens. Bioinformatics (in press).
98. Sturniolo T, Bono E, Ding J, Raddrizzani L, Tuereci O, Sahin U, Braxenthaler M, Gallazzi F, Protti MP, Sinigaglia F, Hammer J. 1999. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat Biotechnol 17:555-561.
99. Su Z, Vieweg J, Weizer AZ, Dahm P, Yancey D, Turaga V, Higgins J, Boczkowski D, Gilboa E, Dannull J. 2002. Enhanced induction of telomerase-specific CD4(+) T cells using dendritic cells transfected with RNA encoding a chimeric gene product. Cancer Res 62:5041-5048.
100. Sylvester-Hvid C, Nielsen M, Lamberth K, Roder G, Justesen S, Lundegaard C, Worning P, Thomadsen H, Lund O, Brunak S, Buus S. 2004. SARS CTL vaccine candidates; HLA supertype-, genome-wide scanning and biochemical validation. Tissue Antigens 63:395-400.
101. Tatsumi T, Kierstead LS, Ranieri E, Gesualdo L, Schena FP, Finke JH, Bukowski RM, Brusic V, Sidney J, Sette A, Logan TF, Kasamon YL, Slingluff CL Jr, Kirkwood JM, Storkus WJ. 2003. MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma. Clin Cancer Res 9:947-954.
102. Thery C, Brachet V, Regnault A, Rescigno M, Ricciardi-Castagnoli P, Bonnerot C, Amigorena S. 1998. MHC class II transport from lysosomal compartments to the cell surface is determined by stable peptide binding, but not by the cytosolic domains of the alpha- and beta-chains. J Immunol 161:2106-2113.
103. Thorsby E. 1997. HLA associated diseases. Hum Immunol 53:1-11.
104. Timmerman JM, Singh G, Hermanson G, Hobart P, Czerwinski DK, Taidi B, Rajapaksa R, Caspar CB, Van Beckhoven A, Levy R. 2002. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res 62:5845-5852.
105. Tourdot S, Oukka M, Manuguerra JC, Magafa V, Vergnon I, Riche N, Bruley-Rosset M, Cordopatis P, Kosmatopoulos K. 1997. Chimeric peptides: a new approach to enhancing the immunogenicity of peptides with low MHC class I affinity: application in antiviral vaccination. J Immunol 159:2391-2398.
106. van Endert PM, Saveanu L, Hewitt EW, Lehner P. 2002. Powering the peptide pump: TAP crosstalk with energetic nucleotides. Trends Biochem Sci 27:454-461.
107. Van Regenmortel MH. 1996. Mapping epitope structure and activity: from one-dimensional prediction to four-dimensional description of antigenic specificity. Methods 9:465-472.
108. Van Regenmortel MH, Pellequer JL. 1994. Predicting antigenic determinants in proteins: looking for unidimensional solutions to a three-dimensional problem? Pept Res 7:224-228.
109. Watts C, Powis S. 1999. Pathways of antigen processing and presentation. Rev Immunogenet 1:60-74.
110. Weber F, Elliott RM. 2002. Antigenic drift, antigenic shift and interferon antagonists: how bunyaviruses counteract the immune system. Virus Res 88:129-136.
111. Wiesmuller KH, Fleckenstein B, Jung G. 2001. Peptide vaccines and peptide libraries. Biol Chem 382:571-579.
112. Williams AP, Peh CA, Purcell AW, McCluskey J, Elliott T. 2002. Optimization of the MHC class I peptide cargo is dependent on tapasin. Immunity 16:509-520.
113. Wu JM, Wu B, Guarnieri F, August JT, Drachman DB. 2001. Targeting antigen-specific T cells by genetically engineered antigen presenting cells. A strategy for specific immunotherapy of autoimmune disease. J Neuroimmunol 106:145-153.
114. Wu TC, Guarnieri FG, Staveley-O'Carroll KF, Viscidi RP, Levitsky HI, Hedrick L, Cho KR, August JT, Pardoll DM. 1995. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci USA 92:11671-11675.
115. York IA, Rock KL. 1996. Antigen processing and presentation by the class I major histocompatibility complex. Annu Rev Immunol 14:369-396.
116. Yu K, Petrovsky N, Schonbach C, Koh JY, Brusic V. 2002. Methods for prediction of peptide binding to MHC molecules: a comparative study. Mol Med 8:137-148.
117. Zagursky RJ, Olmsted SB, Russell DP, Wooters JL. 2003. Bioinformatics: how it is being used to identify bacterial vaccine candidates. Expert Rev Vaccines 2:417-436.
118. Zhao Y, Pinilla C, Valmori D, Martin R, Simon R. 2003. Application of support vector machines for T-cell epitopes prediction. Bioinformatics 19:1978-1984.